Kezar Life Sciences Inc (NASDAQ:KZR)
| 9.27 Delayed Data As of Jul 01 |  +1.00 / +12.09%Today’s Change | 4.31 Today|||52-Week Range 18.55 | -44.56% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $367.3M |
Company Description
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Contact Information
Kezar Life Sciences, Inc. 4000 Shoreline Court South San Francisco California 94080 |
Employees
Shareholders
| Other institutional | 46.64% |
| Mutual fund holders | 31.91% |
| Individual stakeholders | 23.35% |
Top Executives
| John Fowler | Chief Executive Officer & Director |
| Christopher J. Kirk | President, Director & Chief Scientific Officer |
| Michael Wolfe | Director-Finance & Business Operations |
| Marc L. Belsky | Chief Financial Officer & Secretary |
| Noreen Roth Henig | Chief Medical Officer |
